2026-06-14T05:06:05Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/65912024-11-28T17:25:16Zcom_20.500.12105_2173com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19597col_20.500.12105_16960col_20.500.12105_16967col_20.500.12105_16975

00925njm 22002777a 4500 dc Genescà, E author Lazarenkov, A author Morgades, M author Berbis, G author Ruiz-Xivillé, Neus author Gómez-Marzo, P author Ribera, J author Juncà, J author González-Pérez, A author Mercadal, S author Guardia, R author Artola, M T author Moreno, M J author Martinez Lopez, Joaquin author Zamora, L author Barba, P author Gil, C author Tormo, M author Cladera, A author Novo, A author Pratcorona, M author Nomdedeu, J author González-Campos, J author Almeida, M author Cervera, J author Montesinos, P author Batlle, M author Vives, S author Esteve, J author Feliu, E author Solé, F author Orfao, A author Ribera, J M author 2018-07-24 Recurrent deletions of the CDKN2A/ARF/CDKN2B genes encoded at chromosome 9p21 have been described in both pediatric and adult acute lymphoblastic leukemia (ALL), but their prognostic value remains controversial, with limited data on adult T-ALL. Here, we investigated the presence of homozygous and heterozygous deletions of the CDKN2A/ARF and CDKN2B genes in 64 adult T-ALL patients enrolled in two consecutive trials from the Spanish PETHEMA group. Alterations in CDKN2A/ARF/CDKN2B were detected in 35/64 patients (55%). Most of them consisted of 9p21 losses involving homozygous deletions of the CDKNA/ARF gene (26/64), as confirmed by single nucleotide polymorphism (SNP) arrays and interphase fluorescence in situ hybridization (iFISH). Deletions involving the CDKN2A/ARF/CDKN2B locus correlated with a higher frequency of cortical T cell phenotype and a better clearance of minimal residual disease (MRD) after induction therapy. Moreover, the combination of an altered copy-number-value (CNV) involving the CDKN2A/ARF/CDKN2B gene locus and undetectable MRD (≤ 0.01%) values allowed the identification of a subset of T-ALL with better overall survival in the absence of hematopoietic stem cell transplantation. J Hematol Oncol. 2018; 11 (11) : 96. 10.1186/s13045-018-0639-8 1756-8722 1756-8722 Journal of hematology & oncology http://hdl.handle.net/20.500.13003/9207 30041662 L623158983 2-s2.0-85050852307 http://hdl.handle.net/20.500.12105/6591 439693600001 CDKN2A/ARF CDKN2B MRD Prognosis T-ALL Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia